Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Is ADCC the biggest challenge to your biosimilar?


Published on

Informative video by Sartorius Stedim BioOutsource on the challenges presented by ADCC when making a biosimilar.

Published in: Science
  • Be the first to comment

  • Be the first to like this

Is ADCC the biggest challenge to your biosimilar?

  1. 1. Is ADCC the biggest challenge to your biosimilar?
  2. 2. Introduction Sartorius Stedim Biotech (SSB) BioOutsource released a new video, that is now available on-line explaining how to overcome the issues associated with using antibody- dependent cell-mediated cytotoxicity (ADCC) assays. The bite-sized video outlines the factors affecting the use of ADCC assays and discusses what to consider when determining comparability and designing biosimilar drugs. In just five minutes, bioassay development experts, Dr. Catriona Thomson and Dr. Daniel Galbraith describe in this engaging video the challenges of using ADCC assays and explain when to use the different types of assay to assess biosimilars. To watch the video please proceed to the next slide. 2
  3. 3. Any Questions? Contact us (By Phone): Sartorius Stedim BioOutsource Limited 1 Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA. Reception: +44 (0)141 946 4222 Sales: +44 (0)141 948 1291 Contact us (By Web): 3